Momenta Pharmaceuticals CEO Craig Wheeler: An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec outlines the company's efforts to get generic of Sanofi-Aventis' Lovenox to market, its partnership with Sandoz involving biogenerics and other business strategy initiatives.
You may also be interested in...
FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.
FDA Cites Immunogenicity Concerns In “Not Approvable” Letter For Momenta/Sandoz’s Lovenox Generic
Firm is “confident” no immunogenicity differences will arise, Momenta CEO Wheeler says.
Lovenox Clears FDA For STEMI After Priority Review
The low molecular weight heparin joins Plavix in the STEMI space.